Drug Profile


Alternative Names: MD 370503

Latest Information Update: 13 Sep 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antidepressants; Anxiolytics; Oxazoles; Small molecules; Smoking cessation therapies
  • Mechanism of Action Monoamine oxidase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Smoking withdrawal

Most Recent Events

  • 13 Sep 2000 Discontinued-II for Smoking withdrawal in Europe (Unknown route)
  • 13 Sep 2000 Discontinued-II for Smoking withdrawal in USA (Unknown route)
  • 13 Sep 2000 Discontinued-III for Anxiety disorders in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top